Current treatments for type II diabetes mellitus (T2DM) and obesity do not reliably achieve long-term weight-loss and up to 50% of patients experience nausea and vomiting. Thus, there is a critical need for obesity medications that provide glycemic control with enhanced weight loss and without side-effects. We recently reported on the development of EP45, a first in class monomeric peptide drug, which displayed glucoregulation and profound weight loss in rats, and an absence of visceral malaise in shrews, a mammalian model capable of vomiting (unlike rats). By targeting multiple weight-loss and glucoregulatory pathways simultaneously with a single drug, GEP44, we can address multiple coexisting conditions to more efficaciously reduce body weight and blood glucose levels, all devoid of side-effects to improve patient tolerance and quality of life.

Development of anorexigenic and glucoregulatory chimeric peptides with multiagonism of the GLP-1R, Y2-R, and Y1-R to simultaneously treat obesity and type 2 diabetes

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.